Bacterial Toxins—Staphylococcal Enterotoxin B
- Authors: Bettina C. Fries1, Avanish K. Varshney2
- Editors: James E. Crowe Jr.3, Diana Boraschi4, Rino Rappuoli5
-
VIEW AFFILIATIONS HIDE AFFILIATIONSAffiliations: 1: Department of Medicine/Infectious Diseases and Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461; 2: Department of Medicine/Infectious Diseases and Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461; 3: Vanderbilt University School of Medicine, Nashville, TN; 4: National Research Council, Pisa, Italy; 5: Novartis Vaccines, Siena, Italy
-
Received 20 August 2012 Accepted 11 April 2013 Published 13 December 2013
- Correspondence: Bettina C. Fries, [email protected]
- « Previous Article
- Table of Contents
- Next Article »

-
Abstract:
Staphylococcal enterotoxin B is one of the most potent bacterial superantigens that exerts profound toxic effects upon the immune system, leading to stimulation of cytokine release and inflammation. It is associated with food poisoning, nonmenstrual toxic shock, atopic dermatitis, asthma, and nasal polyps in humans. Currently, there is no treatment or vaccine available. Passive immunotherapy using monoclonal antibodies made in several different species has shown significant inhibition in in vitro studies and reduction in staphylococcal enterotoxin B-induced lethal shock in in vivo studies. This should encourage future endeavors to develop these antibodies as therapeutic reagents.
-
Citation: Fries B, Varshney A. 2013. Bacterial Toxins—Staphylococcal Enterotoxin B. Microbiol Spectrum 1(2):AID-0002-2012. doi:10.1128/microbiolspec.AID-0002-2012.




Bacterial Toxins—Staphylococcal Enterotoxin B, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/microbiolspec/1/2/AID-0002-2012-1.gif /docserver/preview/fulltext/microbiolspec/1/2/AID-0002-2012-2.gif

References

Article metrics loading...
Abstract:
Staphylococcal enterotoxin B is one of the most potent bacterial superantigens that exerts profound toxic effects upon the immune system, leading to stimulation of cytokine release and inflammation. It is associated with food poisoning, nonmenstrual toxic shock, atopic dermatitis, asthma, and nasal polyps in humans. Currently, there is no treatment or vaccine available. Passive immunotherapy using monoclonal antibodies made in several different species has shown significant inhibition in in vitro studies and reduction in staphylococcal enterotoxin B-induced lethal shock in in vivo studies. This should encourage future endeavors to develop these antibodies as therapeutic reagents.

Full text loading...
Figures
Alignment of amino acid sequences of SEB derived from S. aureus clinical isolates. Amino acid mutations are highlighted in green. MHC- and TcR-interacting residues are shown in blue and magenta, respectively. doi:10.1128/microbiolspec.AID-0002-2012.f1

Click to view
FIGURE 1
Alignment of amino acid sequences of SEB derived from S. aureus clinical isolates. Amino acid mutations are highlighted in green. MHC- and TcR-interacting residues are shown in blue and magenta, respectively. doi:10.1128/microbiolspec.AID-0002-2012.f1
(A) Ribbon structure of SEB protein showing amino acid mutations in S. aureus isolates. Residues which interact with MHC and TcR are shown in blue and magenta, respectively. (B) View after rotating 180 degrees around vertical axis. doi:10.1128/microbiolspec.AID-0002-2012.f2

Click to view
FIGURE 2
(A) Ribbon structure of SEB protein showing amino acid mutations in S. aureus isolates. Residues which interact with MHC and TcR are shown in blue and magenta, respectively. (B) View after rotating 180 degrees around vertical axis. doi:10.1128/microbiolspec.AID-0002-2012.f2
Tables
Major biological and pathological activities of SEB

Click to view
TABLE 1
Major biological and pathological activities of SEB
List of MAbs generated against SEB toxins

Click to view
TABLE 2
List of MAbs generated against SEB toxins
Supplemental Material
No supplementary material available for this content.